Insider Selling: Portola Pharmaceuticals Director Unloads 1,369 Shares of Stock (PTLA)
Portola Pharmaceuticals (NASDAQ:PTLA) Director Nicholas Galakatos sold 1,369 shares of the stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $23.36, for a total transaction of $31,979.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Portola Pharmaceuticals (NASDAQ:PTLA) opened at 25.01 on Friday. Portola Pharmaceuticals has a 52 week low of $18.25 and a 52 week high of $30.95. The stock has a 50-day moving average of $22.64 and a 200-day moving average of $24.91. The company’s market cap is $1.028 billion.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings data on Monday, May 12th. The company reported ($0.75) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.72) by $0.03. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.81 million. During the same quarter last year, the company posted ($12.94) earnings per share. Portola Pharmaceuticals’s revenue was down 23.8% compared to the same quarter last year. On average, analysts predict that Portola Pharmaceuticals will post $-3.44 earnings per share for the current fiscal year.
Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.